2030 Disease Immune Response 
Drug Discovery World
JANUARY 18, 2024
Poolbeg Pharma, a biopharmaceutical company focused on the development and commercialisation of medicines targeting diseases with a high unmet medical need, has announced promising in vivo results for POLB 001 in addressing cancer immunotherapy-induced cytokine release syndrome (CRS). million cases of cancer by 2030 1,2.
Drug Discovery World
MAY 6, 2024
The company is now investigating a promising gene therapy for Huntingdon’s disease in a Phase I/II trial, with patients already showing signs of preserved neurological function. billion) Healthcare Innovation 2030 project, with ambitious plans to turn France into the European leader in health innovation by 2030. billion ($7.9
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
JULY 11, 2021
Phase 3 study met primary and secondary endpoints demonstrating MenQuadfi ® induced superior immune responses to serogroup C compared to a standard-of-care vaccine in healthy toddlers MenQuadfi is the first and only quadrivalent ACWY vaccine to demonstrate superior immune response against serogroup C in toddlers.
Drug Discovery World
APRIL 12, 2023
In an exclusive interview with The Guardian, Moderna said that cancer and heart disease vaccines would be ready by 2030 1. mRNA-4157/V940 is designed to stimulate an immune response by generating specific T cell responses based on the unique mutational signature of a patient’s tumour.
Drug Discovery World
FEBRUARY 15, 2023
Cancer is a complex heterogenous multistep disease characterised by uncontrolled cell proliferation combined with a dysregulated immune response. Half of people diagnosed with cancer in England and Wales survive their disease for 10 years or more (2010-11) 1. This continues to be the standard of care.
PerkinElmer
JANUARY 25, 2023
Confronting and containing the spread of other infectious diseases like tuberculosis, influenza A and B as well as respiratory syncytial virus (RSV) also remained top global health priorities, as was testing to prevent the transmission of sexually transmitted infections, tickborne diseases and more.
Drug Discovery World
MAY 30, 2023
These targeted cytokines are selectively removed with the intention of neutralising the cancer’s ability to block a patient’s natural immune defence mechanisms, which are significantly compromised in late-stage, metastatic disease. This potentially re-energises the immune system to fight cancers.”
Expert insights. Personalized for you.
162 
Let's personalize your content